Compare · MRK vs RGNT
MRK vs RGNT
Side-by-side comparison of Merck & Company Inc. (MRK) and Regentis Biomaterials Ltd. (RGNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. MRK focuses on Biotechnology: Pharmaceutical Preparations, while RGNT focuses on Industrial Specialties.
- MRK is the larger of the two at $356.13B, about 42607.0x RGNT ($8.4M).
- MRK has been more active in the news (19 items in the past 4 weeks vs 2 for RGNT).
- MRK has more recent analyst coverage (25 ratings vs 0 for RGNT).
- Company
- Merck & Company Inc.
- Regentis Biomaterials Ltd.
- Price
- -
- -
- Market cap
- $356.13B
- $8.4M
- 1M return
- -0.97%
- -
- 1Y return
- +55.70%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Specialties
- Exchange
- NYSE
- AMEX
- IPO
- 2025
- News (4w)
- 19
- 2
- Recent ratings
- 25
- 0
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest MRK
- EVP&Pres, Merck Animal Heallth Deluca Richard R. exercised 58,185 shares at a strike of $77.62 and sold $8,611,875 worth of shares (58,185 units at $148.01), decreasing direct ownership by 0.00% to 112,955 units (SEC Form 4)
- SEC Form 13F-HR filed by Merck & Company Inc.
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- Merck to Participate in the Jefferies Global Healthcare Conference in London
- Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
- FDA Approval for WELIREG issued to MERCK SHARP DOHME
- SEC Form 10-Q filed by Merck & Company Inc.
- Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story
- SEC Form 4 filed by Director Diaz Paul J
- New insider Diaz Paul J claimed ownership of 296 shares (SEC Form 3)
Latest RGNT
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
- Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
- SEC Form EFFECT filed by Regentis Biomaterials Ltd.
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
- SEC Form POS AM filed by Regentis Biomaterials Ltd.
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update